One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Prognostic Factors in Osteosarcoma.
Maki, Robert G. MD, PhD, FACP, FASCO 1,2,3,,; Schwartz, Gary K. MD, FASCO 1,4,5,
doi : 10.1200/JCO.22.02860
Volume 41(27) pgs. 4321-4450 September 20, 2023
Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols.
Bielack, Stefan S.; Kempf-Bielack, Beate; Delling, Gu[Combining Diaeresis]nter; Exner, G. Ulrich; Flege, Silke; Helmke, Knut; Kotz, Rainer; Salzer-Kuntschik, Mechthild; Werner, Matthias; Winkelmann, Winfried; Zoubek, Andreas; Ju[Combining Diaeresis]rgens, Heribert; Winkler, Kurt; for the Cooperative German-Austrian-Swiss Osteosarcoma Study Group
doi : 10.1200/JCO.22.02767
On Cancer Screening During the COVID-19 Pandemic.
Brawley, Otis W. MD, MACP, FRCP(L) 1,,
doi : 10.1200/JCO.23.00284
Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.
Wu, Julie Tsu-yu MD, PhD 1,2,; Wakelee, Heather A. MD 1,; Han, Summer S. PhD 1,3,
doi : 10.1200/JCO.23.01060
Taking It to the States: Adapting Information Blocking Legislation to Oncology.
Gerber, David E. MD 1,
doi : 10.1200/JCO.23.01108
Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
Star, Jessica MA, MPH 1; Bandi, Priti PhD 1,; Siegel, Rebecca L. MPH 1; Han, Xuesong PhD 1,; Minihan, Adair MPH 1; Smith, Robert A. PhD 2; Jemal, Ahmedin DVM, PhD 1,
doi : 10.1200/JCO.22.02170
Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
Irajizad, Ehsan PhD 1; Fahrmann, Johannes F. PhD 2,; Marsh, Tracey PhD 3,; Vykoukal, Jody PhD 2; Dennison, Jennifer B. PhD 2,; Long, James P. PhD 1; Do, Kim-Anh PhD 1; Feng, Ziding PhD 3,; Hanash, Samir MD, PhD 2,; Ostrin, Edwin J. MD, PhD 4,,
doi : 10.1200/JCO.22.02424
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg, Nanda MD, PhD 1,,; Nout, Remi A. MD, PhD 1,2,; Jurgenliemk-Schulz, Ina M. MD, PhD 3; Lutgens, Ludy C.H.W. MD, PhD 4; Jobsen, Jan J. MD, PhD 5; Haverkort, Marie A.D. MD 6; Mens, Jan Willem M. MD 2; Slot, Annerie MD 7; Wortman, Bastiaan G. MD, PhD 1,8; de Boer, Stephanie M. MD, PhD 1,; Stelloo, Ellen PhD, MSc 9; Verhoeven-Adema, Karen W. PhD 10; Putter, Hein PhD 11; Smit, Vincent T.H.B.M. MD, PhD 9; Bosse, Tjalling MD, PhD 9; Creutzberg, Carien L. MD, PhD 1,; for the PORTEC Study Group; Creutzberg, C.L.; Koper, P.C.M.; van Putten, W.L.J.; Dercksen, R.; van Lent, M.; Beerman, H.; Lybeert, M.L.M.; Jobsen, J.J.; Meerwaldt, J.H.; Warlam-Rodenhuis, C.C.; De Winter, K.A.J.; Lutgens, L.C.H.W.; van den Bergh, A.C.M.; van de Steen-Banasik, E.M.; Stenfert Kroese, M.C.; Pop, L.A.M.; Uitterhoeve, L.; Snijders-Keilholz, A.A.; van Bunningen, B.N.F.M.; Biesta, J.H.; Gescher, F.M.; Pomp, J.; Meijer, O.W.M.; Tabak, J.H.; Slot, A.; Jurgenliemk-Schulz, I.M.; van der Steen-Banasik, E.M.; Mens, J.W.M.; Nout, R.A.; Smit, V.T.H.B.M.; Leer, J.W.; Timmer, P.R.; van Triest, B.; Pras, B.; Wiggenraad, R.; Gescher, F.; Coen, V.L.M.
doi : 10.1200/JCO.23.00062
Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.
Im, Cindy PhD 1,; Sharafeldin, Noha PhD 2,3; Yuan, Yan PhD 4; Wang, Zhaoming PhD 5,6; Sapkota, Yadav PhD 5; Lu, Zhanni DrPH 1; Spector, Logan G. PhD 1; Howell, Rebecca M. PhD 7,; Arnold, Michael A. MD 8,; Hudson, Melissa M. MD 5,9,; Ness, Kirsten K. PhD 5; Robison, Leslie L. PhD 5; Bhatia, Smita MD 3; Armstrong, Gregory T. MD 5,9; Neglia, Joseph P. MD 1; Yasui, Yutaka PhD 4,5; Turcotte, Lucie M. MD 1
doi : 10.1200/JCO.23.00428
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
Kim, Chang Gon MD, PhD 1,; Jung, Minkyu MD, PhD 1,; Kim, Hyo Song MD, PhD 1; Lee, Choong-kun MD, PhD 1,; Jeung, Hei-Cheul MD, PhD 2; Koo, Dong-Hoe MD, PhD 3; Bae, Woo Kyun MD, PhD 4; Zang, Dae Young MD, PhD 5; Kim, Bum Jun MD, PhD 5; Kim, Hyunki MD, PhD 6; Yun, Un-Jung PhD 1,7; Che, Jingmin MS 7,8; Park, Sejung PhD 7; Kim, Tae Soo PhD 7; Kwon, Woo Sun PhD 7; Park, Juin BS 7,9; Cho, Sang Woo BS 7,10; Nam, Chung Mo PhD 11; Chung, Hyun Cheol MD, PhD 1,; Rha, Sun Young MD, PhD 1,10,,
doi : 10.1200/JCO.22.02122
Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
Swinton, Martin MBBChir 1,2,; Mariam, Neethu Billy Graham MBChB 1; Tan, Jean Ling MBChB 2; Murphy, Katherine MBChB 3; Elumalai, Thiraviyam MD 4,; Soni, Manjusha MBBS, MD 5; Ferrera, Alexandra MBChB 1; Richardson, Charlotte MBChB 5; Walshaw, Richard MBChB, PhD 3,; Mistry, Hitesh PhD 2; Ramani, Vijay MBBS 1; Song, Yeepei MBBCh, MD 1,; Birtle, Alison MBBS, MD 6,; Henry, Ann MBChB, MD 5,; Chan, Joachim MBBS, MD 3; Hoskin, Peter MD 2,; Choudhury, Ananya MA, PhD 1,2,
doi : 10.1200/JCO.23.00725
Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein, Sarah A. MD, PhD 1,,; Grant, Shakira J. MBBS 2; Wildes, Tanya M. MD, MCSI 1,
doi : 10.1200/JCO.23.00512
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Singh, Navneet MD, DM, FASCO 1; Daly, Megan E. MD 2,; Ismaila, Nofisat MD, MSc 3,; for the Management of Stage III NSCLC Guideline Expert Panel; Daly, Megan E. MD; Singh, Navneet MD, DM; Antonoff, Mara B. MD; Arenberg, Douglas A. MD; Bradley, Jeffrey MD; David, Elizabeth MD; Detterbeck, Frank MD; Fruh, Martin MD; Gubens, Matthew A. MD, MS; Moore, Amy C. PhD; Padda, Sukhmani K. MD; Patel, Jyoti D. MD; Phillips, Tanyanika MD, MPH; Qin, Angel MD; Robinson, Clifford MD; Simone, Charles B. II MD
doi : 10.1200/JCO.23.01261
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
Litton, Jennifer K. MD 1,,; Regan, Meredith M. PhD 2,; Pusztai, Lajos MD, PhD 3,; Rugo, Hope S. MD 4,; Tolaney, Sara M. MD 5,; Garrett-Mayer, Elizabeth PhD 6; Amiri-Kordestani, Laleh MD 7; Basho, Reva K. MD 8,; Best, Ana F. PhD 9; Boileau, Jean-Francois MD 10,; Denkert, Carsten MD 11,; Foster, Jared C. PhD 9; Harbeck, Nadia MD, PhD 12,; Jacene, Heather A. MD 13,; King, Tari A. MD 14,; Mason, Ginny RN, BSN 15,; O'Sullivan, Ciara C. MBBCH 16,; Prowell, Tatiana M. MD 7,17; Richardson, Andrea L. MD, PhD 18,; Sepulveda, Karla A. MD 19; Smith, Mary Lou JD, MBA 20,; Tjoe, Judy A. MD 21; Turashvili, Gulisa MD 22; Woodward, Wendy A. MD, PhD 23,; Butler, Lynn Pearson MS 24; Schwartz, Elena I. MD, PhD 25; Korde, Larissa A. MD, MPH 26
doi : 10.1200/JCO.23.00435
Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
McCaw, Zachary R. PhD; Richardson, Paul G. MD; Wei, Lee-Jen PhD
doi : 10.1200/JCO.23.00465
Reply to Z.R. McCaw et al.
Farrar, Jason E. MD; Othus, Megan PhD; Wang, Yi-Cheng MS; Alonzo, Todd A. PhD; Meshinchi, Soheil MD, PhD
doi : 10.1200/JCO.23.00986
Retraction: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
doi : 10.1200/JCO.23.01358
Erratum: Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
doi : 10.1200/JCO.23.01228
Erratum: Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.
doi : 10.1200/JCO.23.01583
Erratum: Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.
doi : 10.1200/JCO.23.01537
